

Adcirca (Alyq, tadalafil 20mg)

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pa	tient's Name:	_Date:
Pa	tient's ID:	Patient's Date of Birth:
Ph	ysician's Name:	NPI#:
Sp	ecialty:	NPI#:
Ph	ysician Office Telephone:	Physician Office Fax:
Re	quest Initiated For:	-
1.	What drug is being prescribed? \Box Adcirca \Box	Alyq □ tadalafil 20mg □ Other
2.	What is the diagnosis? ☐ Pulmonary arterial hypertension (PAH) ☐ Secondary Raynaud's phenomenon ☐ Erectile dysfunction ☐ Other	
3.	What is the ICD-10 code?	_
4.	If brand Adcirca is being prescribed, is the prescribed prescription to the pharmacy and skip to # Yes - tadalafil 20mg ☐ Yes - Alyq ☐ No ☐ Not applicable - brand Adcrica is not being respectively.	
5.	Has the patient failed treatment with the generic vomiting)? \square Yes \square No	medication due to an intolerable adverse event (e.g., rash, nausea
6.		dverse event attributed to the <u>active</u> ingredient as described in the ction for both the brand and generic medication)? \square Yes \square No
7.	Provide SPECIFIC and DETAILED chart doc adverse event, dosage and duration of generic n	TION REQUIRED: Documentation is required for approval. umentation including description, date/time, and severity of the medication treatment, required intervention (if any), and edWatch form of this trial and failure including the adverse
8.	Is the request for continuation of therapy with th \square Yes \square No <i>If No, skip to diagnosis section</i>	ne requested medication?
9.	Is the patient currently receiving the requested m ☐ Yes ☐ No ☐ Unknown If No or Unknown	nedication through a paid pharmacy or medical benefit? n, skip to diagnosis section

Send completed form to: Case Review Unit CVS Caremark Prior Authorizations Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Addirca [Alyq, tadalafil 20mg] ACSF SGM - 7/2022.

10. Is the patient experiencing a benefit from therapy with the requested medication as evidenced by disease stability or disease improvement? ☐ Yes ☐ No No further questions			
Complete the following section based on the patient's diagnosis, if applicable.			
Section A: Pulmonary Arterial Hypertension (PAH) 11. What is the World Health Organization (WHO) classification of pulmonary hypertension? WHO Group 1 (Pulmonary arterial hypertension) WHO Group 2 (Pulmonary hypertension owing to left heart disease) WHO Group 3 (Pulmonary hypertension owing to lung disease and/or hypoxia) WHO Group 4 (Chronic thromboembolic pulmonary hypertension) WHO Group 5 (Pulmonary hypertension with unclear multifactorial mechanisms)			
12. Has PAH been confirmed by right heart catheterization? ☐ Yes ☐ No. If No. skip to #16			
13. What is the pretreatment mean pulmonary arterial pressure at rest? mmHg			
14. What is the pretreatment pulmonary capillary wedge pressure? mmHg			
15. What is the pretreatment pulmonary vascular resistance? Wood units No further questions			
16. Has Doppler echocardiogram been performed to diagnose PAH? ☐ Yes ☐ No			
Section B: Secondary Raynaud's Phenomenon 17. Has the patient had an inadequate response to one of the following medications? Calcium channel blockers Angiotensin receptor blockers Selective serotonin reuptake inhibitors Alpha blockers Topical nitrates Other			
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.			
X			

Send completed form to: Case Review Unit CVS Caremark Prior Authorizatons Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please